Challenges and prospects of CSF1R targeting for advanced malignancies

CSF1R expression modulates tumor-associated macrophages, making CSF1R blockade an appealing immune-modulating therapeutic target. We evaluated the correlation between CSF1R tumor RNA expression and outcome (pan-cancer setting). RNA expression was ranked as a percentile (0-100) using a standardized i...

Full description

Saved in:
Bibliographic Details
Published in:American journal of cancer research 2023-01, Vol.13 (7), p.3257-3265
Main Authors: Moeller, Ann, Kurzrock, Razelle, Botta, Gregory P, Adashek, Jacob J, Patel, Hitendra, Lee, Suzanna, Pabla, Sarabjot, Nesline, Mary K, Conroy, Jeffrey, Sicklick, Jason K, Kato, Shumei
Format: Article
Language:English
Subjects:
Brief Communication
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:CSF1R expression modulates tumor-associated macrophages, making CSF1R blockade an appealing immune-modulating therapeutic target. We evaluated the correlation between CSF1R tumor RNA expression and outcome (pan-cancer setting). RNA expression was ranked as a percentile (0-100) using a standardized internal reference population (735 tumors; 35 histologies). Among 514 patients, there was no difference in survival from biopsy between high and low CSF1R expressors (< 50 percentile versus ≥ 50 percentile rank). There was also no significant difference in median progression-free or overall survival (from treatment) based on CSF1R expression in 21 patients who received CSF1R inhibitors (all values ≥ 0.08). Concurrent upregulation of ≥ 2 additional immune checkpoint markers (e.g. PD-L1, BTLA, CTLA4, LAG3, TIM3) was observed in all tumor samples with CSF1R expression ≥ 50th percentile. Pending further large prospective studies, patients with high tumor CSF1R expression may need treatment that co-targets the specific immune checkpoint pathways activated in order to impact outcome.
ISSN:2156-6976
2156-6976